Matthew Gallagher grew up moving between motels, with a disabled father and parents battling addiction. By age five he was hawking “pretty rocks” door to door; in elementary school he sold origami on the school bus. That early hustle pushed him into Harvard and then a stint in venture capital. His first startup, Watch Gang, exploded to $11 million revenue in 2017 but collapsed under the weight of 60 employees and bloated costs. He learned a hard lesson: head count kills profitability. When GLP-1 weight-loss drugs surged in 2024, Gallagher saw a market gap. He outsourced everything high-risk or heavy—CareValidate for prescriptions, OpenLoop Health for shipping—and built only the front end himself. In two months he launched MEDVi, using a dozen AI tools (ChatGPT, Claude, Grok for code and copy; Midjourney, Runway for ads; ElevenLabs for customer service). He handled branding, ad ops, payment flow and support, leaving compliance and logistics to partners. MEDVi hit 300 customers in month one and 1,300 in month two. By year’s end it had 250,000 users, $400 million in revenue and a 16.2 percent net margin—twice that of rivals like Hims & Hers. For 2026 he’s targeting $1.8 billion. Critics accuse him of “grey-area” marketing tactics, but his solo run (with only his brother onboard) has reshaped what a one-person unicorn can look like.